HealthQuill Fast Track Approval
SAB Biotherapeutics got a fast-track designation from the USFDA for its investigational drug to treat influenza in high-risk and immunocompromised patients.
Drugs Medical Pharma

SAB gets FDA fast track nod for experimental drug to treat influenza

HQ Team April 14, 2023: SAB Biotherapeutics got a fast-track designation from the USFDA for its investigational drug to treat influenza in high-risk.

Read More